Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 4/20 | 0.46 |
| ▸ | JAK1 | P23458 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 4/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 6/20 | 0.45 |
| ▸ | FLT4 | P35916 | 4/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29249034 | 1.00 | JAK3 (0.46) | JAK3JAK1JAK2DDR2FLT4 | |
| SCHEMBL22090272 | 0.95 | DDR2 (0.49) | JAK3JAK1JAK2DDR2 | |
| SCHEMBL28612297 | 0.95 | DDR2 (0.49) | JAK3JAK1JAK2DDR2 | |
| SCHEMBL29942255 | 0.95 | DDR2 (0.49) | JAK3JAK1JAK2DDR2 | |
| SCHEMBL22089923 | 0.93 | JAK3 (0.48) | JAK3JAK1JAK2DDR2FLT4 | |
| SCHEMBL28919837 | 0.93 | JAK3 (0.48) | JAK3JAK1JAK2DDR2FLT4 | |
| SCHEMBL29941940 | 0.93 | JAK3 (0.48) | JAK3JAK1JAK2DDR2FLT4 | |
| SCHEMBL28614744 | 0.91 | DDR2 (0.49) | JAK3JAK1DDR2FLT4KDR | |
| SCHEMBL22097837 | 0.91 | JAK3 (0.49) | JAK3JAK1JAK2DDR2FLT4 | |
| SCHEMBL27171229 | 0.91 | JAK3 (0.49) | JAK3JAK1JAK2DDR2FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119118999-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118955477-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118903141-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118903142-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-113227074-B | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118388457-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| CN-118290403-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230002362-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | JAK3 3/4885JAK1 2/4885JAK2 1/4885 |
| US-20230002362-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | JAK3 2/4885JAK1 1/4885JAK2 3/4885 |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK2, JAK1, JAK3 | JAK3 3/4885JAK1 2/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.